Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02456701 · ClinicalTrials.gov registry record · Phase 1
Enhancing Radioiodine Incorporation Into BRAF Mutant Thyroid Cancers With the Combination of Vemurafenib and KTN3379
A Phase 1 study, sponsored by Celldex Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 7
- Enrollment target
NCT02456701 is a Phase 1 study that has completed, run by Celldex Therapeutics. The registered enrollment target is 7 participants.
The verdict
NCT02456701, a Phase 1 study, has completed, sponsored by Celldex Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 7 participants
- Enrollment target
Study Summary
This is a patient pilot study testing the hypothesis that vemurafenib with the addition of KTN3379 can restore iodine incorporation in BRAF mutant (MUT), radioiodine-refractory (RAIR) thyroid cancer patients.
Interventions
- DRUG vemurafenib
- BIOLOGICAL KTN3379
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2015-06 |
| Est. Completion | 2016-10-13 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02456701
The ClinicalTrials.gov registry entry for NCT02456701 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Celldex Therapeutics, which has 42 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which vemurafenib is the first listed.
NCT02456701 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02456701 about?
NCT02456701 is a clinical study titled "Enhancing Radioiodine Incorporation Into BRAF Mutant Thyroid Cancers With the Combination of Vemurafenib and KTN3379". This is a patient pilot study testing the hypothesis that vemurafenib with the addition of KTN3379 can restore iodine incorporation in BRAF mutant (MUT), radioiodine-refractory (RAIR) thyroid cancer patients.
What is the current status of trial NCT02456701?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 7 participants. The study started on 2015-06. Estimated completion is 2016-10-13.
What interventions are being tested in trial NCT02456701?
The interventions under investigation include: vemurafenib (DRUG), KTN3379 (BIOLOGICAL).
Who is sponsoring clinical trial NCT02456701?
This trial is sponsored by Celldex Therapeutics, which has 42 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.